Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Czechsinthemail who wrote (388)	12/10/1998 12:11:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4474

Baird: Sort of general questions for me to field. I have long thought that a combo of CEGE technology and that of ARIA was an amazing fit, and once suggested to Gordon Binder -- before the Hoechst deals -- that he fund joint development projects from the two companies. IMO, ARIA is most advanced at control of both "effector" function and its elimination through apoptosis. However and IMO, ol' Harvey has not provided an optimal infrastructure to take full advantage of this conceptual lead. Here's something fun for ol' Harvey to chew on...... "The Market for Osteoporosis Therapies Will Exceed $9 Billion by 2007"........ prnewswire.com